ras p21 expression in relation to DNA ploidy, S-phase fraction and prognosis in colorectal adenocarcinoma

S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma

“…Recent experiences that demonstrated a relation between high SPF values and oncogene ras expression15 may help explain the worse behavior of these tumors. These data emphasize the need for investigations on the use of adjuvant chemotherapy in subsets of Stage I patients with a poor prognosis.…”

“…S‐phase fraction (SPF) is an additional DNA index determined by flow cytometry that showed prognostic power similar to ploidy 9, 10. Recent data indicate that high SPF significantly correlates with oncogene product ras p21 overexpression 15. In addition, SPF analysis demonstrated prognostic differences among diploid colorectal tumors 16…”

S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma

“…Recent experiences that demonstrated a relation between high SPF values and oncogene ras expression15 may help explain the worse behavior of these tumors. These data emphasize the need for investigations on the use of adjuvant chemotherapy in subsets of Stage I patients with a poor prognosis.…”

“…S‐phase fraction (SPF) is an additional DNA index determined by flow cytometry that showed prognostic power similar to ploidy 9, 10. Recent data indicate that high SPF significantly correlates with oncogene product ras p21 overexpression 15. In addition, SPF analysis demonstrated prognostic differences among diploid colorectal tumors 16…”

Tumour markers of prognosis in colorectal cancer

“…Tumour staining for p21 was found in 54% (216/399) of tumours, but varied between studies (31-71% positive). Positive staining for p21 was associated with a poor prognosis in three out of four studies (Miller et al, 1992;Sun et al, 1991;Miyahara et al, 1991) and was shown to be an independent prognostic factor in only one study (Sun et al, 1991). Although there are concerns about the methodology (non-specific ras antibody, criteria for 'positive' expression) and statistical analyses used in these studies, there is an overall indication that tumour staining for p21 is associated with a poor prognosis and should be considered for inclusion in more definitive studies of markers of prognostic significance in colorectal cancer.…”

“…Immunohistochemical analysis of ras p21 staining and outcome has been performed in four studies (a total of 399 patients) (Miyahara et al, 1991;Sun et al, 1991;Miller et al, 1992;Bennett et al, 1995). Different monoclonal antibodies were used in all studies and the method of scoring a tumour p21 as 'positive' either was not detailed or differed between the studies.…”

S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma

“…Recent experiences that demonstrated a relation between high SPF values and oncogene ras expression15 may help explain the worse behavior of these tumors. These data emphasize the need for investigations on the use of adjuvant chemotherapy in subsets of Stage I patients with a poor prognosis.…”

“…S‐phase fraction (SPF) is an additional DNA index determined by flow cytometry that showed prognostic power similar to ploidy 9, 10. Recent data indicate that high SPF significantly correlates with oncogene product ras p21 overexpression 15. In addition, SPF analysis demonstrated prognostic differences among diploid colorectal tumors 16…”

Tumour markers of prognosis in colorectal cancer

“…Tumour staining for p21 was found in 54% (216/399) of tumours, but varied between studies (31-71% positive). Positive staining for p21 was associated with a poor prognosis in three out of four studies (Miller et al, 1992;Sun et al, 1991;Miyahara et al, 1991) and was shown to be an independent prognostic factor in only one study (Sun et al, 1991). Although there are concerns about the methodology (non-specific ras antibody, criteria for 'positive' expression) and statistical analyses used in these studies, there is an overall indication that tumour staining for p21 is associated with a poor prognosis and should be considered for inclusion in more definitive studies of markers of prognostic significance in colorectal cancer.…”

“…Immunohistochemical analysis of ras p21 staining and outcome has been performed in four studies (a total of 399 patients) (Miyahara et al, 1991;Sun et al, 1991;Miller et al, 1992;Bennett et al, 1995). Different monoclonal antibodies were used in all studies and the method of scoring a tumour p21 as 'positive' either was not detailed or differed between the studies.…”

S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma

“…Recent experiences that demonstrated a relation between high SPF values and oncogene ras expression15 may help explain the worse behavior of these tumors. These data emphasize the need for investigations on the use of adjuvant chemotherapy in subsets of Stage I patients with a poor prognosis.…”

“…S‐phase fraction (SPF) is an additional DNA index determined by flow cytometry that showed prognostic power similar to ploidy 9, 10. Recent data indicate that high SPF significantly correlates with oncogene product ras p21 overexpression 15. In addition, SPF analysis demonstrated prognostic differences among diploid colorectal tumors 16…”

Tumour markers of prognosis in colorectal cancer

“…Tumour staining for p21 was found in 54% (216/399) of tumours, but varied between studies (31-71% positive). Positive staining for p21 was associated with a poor prognosis in three out of four studies (Miller et al, 1992;Sun et al, 1991;Miyahara et al, 1991) and was shown to be an independent prognostic factor in only one study (Sun et al, 1991). Although there are concerns about the methodology (non-specific ras antibody, criteria for 'positive' expression) and statistical analyses used in these studies, there is an overall indication that tumour staining for p21 is associated with a poor prognosis and should be considered for inclusion in more definitive studies of markers of prognostic significance in colorectal cancer.…”

“…Immunohistochemical analysis of ras p21 staining and outcome has been performed in four studies (a total of 399 patients) (Miyahara et al, 1991;Sun et al, 1991;Miller et al, 1992;Bennett et al, 1995). Different monoclonal antibodies were used in all studies and the method of scoring a tumour p21 as 'positive' either was not detailed or differed between the studies.…”